Compare BioNano Genomics Inc (BNGO) vs Stanley Black & Decker, Inc. (SWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Stanley Black & Decker, Inc. — how do they compare? BioNano Genomics Inc trades at $1.24 (market cap $13.66M), while Stanley Black & Decker, Inc. trades at $103.91 (market cap $15.71B). The key difference: Stanley Black & Decker, Inc. is far larger — about 1150.1× BioNano Genomics Inc's market cap, and Stanley Black & Decker, Inc. pays a 3.23% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | SWK | |
|---|---|---|
Market Cap | $13.66M | $15.71B |
Sector | Health | — |
52-Week High | $4.92 | $104.00 |
52-Week Low | $1.06 | $62.12 |
Enterprise Value | $16.26M | $19.87B |
Dividend Yield | — | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
Stanley Black & Decker (SWK) trades at $103.11, up 0.46% today, with a bullish technical signal from moving averages but overbought RSI readings near 80. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $1.57 exceeding expectations by 30%. Recent news highlights a $1 billion U.S. investment plan and strong institutional buying, while fundamentals show improving margins and debt reduction progress.
SWK presents a mixed outlook: positive earnings momentum and strategic initiatives support upside, but valuation appears stretched with a P/E of 25.4 above sector averages. Risks include competitive pressures and macroeconomic sensitivity. Analyst consensus is cautious with a hold-heavy rating and $93.67 price target below current levels, suggesting limited near-term upside despite operational improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →
